Earnings Previews: Bitfarms, Mind Medicine, SAIC, Xpeng
Here are previews of four interesting companies set to report quarterly results before markets open on Monday.
Definium Therapeutics, Inc. (NASDAQ: DFTX) is a pre-revenue, late-stage clinical biopharmaceutical company developing psychedelic-derived therapeutics intended to address underlying causes of psychiatric and neurological disorders.
Its lead candidate, DT120 ODT, is a proprietary, pharmaceutically optimized orally disintegrating tablet of lysergide (LSD) tartrate. It acts as a partial agonist at 5-HT2A receptors and uses Catalent's Zydis fast-dissolve technology.
- **GAD:** positive results from three Phase 3 studies in GAD and MDD (Voyage, Panorama and Emerge), with an NDA filing targeted for the first half of 2027.
- **MDD:** the Phase 3 Ascend study is enrolling.
- **PTSD:** the Phase 3 Haven study is planned for 2027.
- DT120 holds FDA Breakthrough Therapy designation in both GAD and MDD.
The second program, DT402, is a proprietary R(-)-MDMA enantiomer being developed for core symptoms of autism spectrum disorder. It showed positive initial Phase 2a results.
The company is building commercial-readiness capabilities ahead of a potential launch. Any launch would depend on FDA approval and DEA/state rescheduling of Schedule I substances. Definium held approximately $1.05 billion in cash, cash equivalents and investments, which it expects to fund operations into 2030. Updated
Here are previews of four interesting companies set to report quarterly results before markets open on Monday.
Here's a quick look at six publicly traded companies developing ways to use psychedelics to treat mental health issues.
Definium Therapeutics, Inc. (NASDAQ: DFTX) is a pre-revenue, late-stage clinical biopharmaceutical company developing psychedelic-derived therapeutics intended to address underlying causes of psychiatric and neurological disorders.